FAKTOR OPTIONSSCHEIN - BIOMERIEUX Share Price

Certificat

DE000GB28HZ3

Market Closed - BOERSE MUENCHEN 19:27:04 28/06/2024 BST
1.95 EUR -8.92% Intraday chart for FAKTOR OPTIONSSCHEIN - BIOMERIEUX
Current month-23.53%
1 month-20.05%
Date Price Change
28/06/24 1.95 -8.92%
27/06/24 2.141 -3.90%
26/06/24 2.228 +0.09%
25/06/24 2.226 +8.06%
24/06/24 2.06 +1.03%

Real-time BOERSE MUENCHEN

Last update June 28, 2024 at 07:27 pm

More quotes

Static data

Product typeExotische Produkte
Buy / SellCALL
Underlying BIOMÉRIEUX
Issuer Goldman Sachs
WKN GB28HZ
ISINDE000GB28HZ3
Date issued 11/09/2019
Strike 60.13
Maturity Unlimited
Parity 14.25 : 1
Emission price 10
Emission volume N/A
Settlement Barausgleich
Currency EUR

Technical Indicators

Highest since issue 18.92
Lowest since issue 1.95
Spread 0.2
Spread %9.26%

Company Profile

bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows: - medical applications (84.4%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors; - industrial applications (15.6%). The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services. Net sales are distributed geographically as follows: Europe/Middle East/Africa (32.4%), North America (44.1), Asia/Pacific (17.3%) and Latin America (6.2%).
Sector
-
More about the company

Ratings for bioMérieux

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: bioMérieux

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
88.75 EUR
Average target price
113.5 EUR
Spread / Average Target
+27.86%
Consensus